Pfizer’s Phase 2b/3 ritlecitinib trial meets primary endpoint
The randomised, placebo-controlled, double-blind Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Aug 21
The randomised, placebo-controlled, double-blind Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth,…
04 Aug 21
The acquisition of Translate Bio will help French drugmaker Sanofi to further advance the development of transformative medicines…
03 Aug 21
The FDA approval was based on efficacy and safety data from the Saphnelo clinical development programme, including two…
03 Aug 21
Moderna will make an upfront payment for each target it licensed from Autolus, in addition to milestone payments…
02 Aug 21
Takeda has granted HilleVax exclusive global development and commercialisation rights to its norovirus vaccine candidate, excluding Japan
02 Aug 21
The new IV formulation is said to allow for uninterrupted treatment for PAH patients who are temporarily unable…
30 Jul 21
We find out why sponsors and regulators are finally working to increase patient engagement across the life cycle…
30 Jul 21
The partnership will discover, develop and commercialise novel small molecules that stimulate tumour-specific immune responses
30 Jul 21
The FDA approval is supported by data from the SYNAPSE study that assessed the effect of Nucala in…
29 Jul 21
Sotrovimab is a SARS-CoV-2 monoclonal antibody intended to treat Covid-19 in adults and adolescents, aged 12 years and…